Health Decisions (Durham, NC) has a new company in its Agile Clinical Network, a community of research partners with the goal of higher efficiency standards in complex global studies.KLIXAR, an Argentinian CRO, has received certification after completing "rigorous" training in Agile Clinical development techniques.
“Our alliance with Health Decisions will enable us to broaden our customer base while providing unparalleled efficiency and transparency to pharmaceutical companies in Latin America,” said said Enrique Gaubeca, managing director at KLIXAR, in a company press release.
As part of the newly launched Network, KLIXAR will have access to Health Decisions’ data management systems, biostatistics expertise, medical writers, advanced data collection tools, and real-time reporting capabilities.
"We look forward to working with KLIXAR and all our Agile Clinical Network partners to raise the standards of efficiency for global clinical trials," said Rick Farris, COO at Health Decisions. "By producing rapid, accurate results for our sponsors regardless of geographic boundaries, we hope to shape the future of drug development..."
For more information about the Network, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.